Efficacy and Safety of Sirolimus in LAM

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

89 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-31

Study Completion Date

2011-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Lymphangioleiomyomatosis (LAM) is a rare lung disease of women that is caused by genetic mutations. It results in the uncontrolled growth of an unusual type of smooth muscle cell in the lung. These cells invade lung tissue, including the airways, blood vessels, and lymph vessels, and restrict the flow of air, blood, and lymph, respectively. Respiratory failure, lung collapse (pneumothorax), and pleural effusions (chylothorax) are hallmarks of the disease. This study will evaluate the safety and effectiveness of sirolimus, an inhibitor of the mTOR pathway, in stabilizing or improving lung function in people with LAM.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Discovery of Sirolimus Sensitive Biomarkers in Blood

NCT03304678

Lymphangioleiomyomatosis

COMPLETED PHASE2

The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)

NCT02116712

Pulmonary Lymphangioleiomyomatosis

COMPLETED PHASE1

Safety and Durability of Sirolimus for Treatment of LAM

NCT02432560

Lymphangioleiomyomatosis

RECRUITING

Rapamycin Therapy for Patients With Tuberous Sclerosis Complex and Sporadic LAM

NCT00457808

Tuberous Sclerosis Lymphangioleiomyomatosis

COMPLETED PHASE2

Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM

NCT00490789

Tuberous Sclerosis Lymphangioleiomyomatosis

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

LAM is an uncommon, progressive, cystic lung disease that predominantly affects young women. The disease is caused by mutations in tuberous sclerosis complex (TSC) genes, which regulate cellular pathways that control nutrient sensing, cell size, cell migration, and cell proliferation. Individuals with LAM often experience pneumothorax and chylothorax, as well progressive loss of lung function. Sirolimus is drug that was approved for the prevention of kidney transplant rejection. It directly affects the cellular pathway that causes LAM. This study will evaluate the safety and effectiveness of sirolimus in stabilizing or improving lung function in people with LAM.

Individuals interested in participating in this 2-year, double-blind study will first report to the study sites for pulmonary function testing to determine their eligibility for participation. Participants deemed eligible will be randomly assigned to receive either sirolimus or placebo for 1 year. Sirolimus or placebo will be administered in 2 tablet doses (2 mg for sirolimus) for the duration of the study. Study visits will occur at baseline, Week 3, every 3 months for 12 months, and months 18 and 24. Study visits will include a physical exam, questionnaires, a pregnancy test, blood and urine collection, and functional lung tests. A 6-minute walk test will occur at most study visits; a chest x-ray will be taken at baseline and month 24; and a volumetric computed tomography scan will occur at baseline, month 12, and month 24. Adverse events, medication side effects, and lung function will be assessed at each visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lymphangioleiomyomatosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Unlabeled sirolimus tablets were provided by Pfizer. Identical appearing placebo tablets were obtained from a commercial source. Sirolimus levels were reported only to the medical monitor. To maintain the blind, when dose adjustments were made in the sirolimus group, a sham adjustment was also made in the placebo group

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active Agent (Sirolimus)

Participants receive sirolimus daily for 1 year and are followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.

Group Type EXPERIMENTAL

Sirolimus

Intervention Type DRUG

A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.

Placebo Arm

Participants receive placebo daily for 1 year and followed with serial pulmonary function tests, 6-minute walk tests, and symptom and QOL questionnaires over a 2-year period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

A placebo dose of 2 tablets per day for 1 year.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sirolimus

A sirolimus dose of 2 tablets (1 mg/tablet) per day for 1 year.

Intervention Type DRUG

Placebo

A placebo dose of 2 tablets per day for 1 year.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Rapamycin Other names: placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 or older
* Signed and dated informed consent
* Diagnosis of LAM based on compatible chest CT scan and a) biopsy or cytology consistent with LAM, or b) presence of tuberous sclerosis, angiomyolipoma or chylous pleural effusion; or c) a VEGF-D level of at least 800 pg/ml
* Forced expiratory volume in one second (FEV1) of 70% or less of predicted value after administration of a bronchodilator

Exclusion Criteria

* Known allergy to sirolimus
* History of heart attack, angina, or stroke due to clogging, narrowing, and hardening of the arteries and blood vessels
* Significant hematologic or hepatic abnormality (transaminase levels greater than three times the upper limit of normal, HCT less than 30%, platelets less than 80,000/cubic mm, adjusted absolute neutrophil count less than 1,000/cubic mm, total white blood cell count less than 3,000/cubic mm)
* Intercurrent infection at the time treatment with sirolimus begins
* Any surgery involving entry into a body cavity or requiring three or more sutures within 8 weeks of initiation of study drug
* Use of an investigational drug within the 30 days prior to random assignment
* Uncontrolled hyperlipidemia
* Previous lung transplant or currently on lung transplant list
* Unable to attend scheduled study visits
* Unable to perform pulmonary function tests
* Creatinine levels greater than 2.5 mg/dl
* Chylous ascites severe enough to affect diaphragmatic function
* Pleural effusion severe enough to affect pulmonary function, as determined by the study physician
* History of acute pneumothorax within the 2 months prior to study entry
* History of malignancy within the 2 years prior to study entry (except for squamous or basal cell skin cancer)
* Use of estrogen containing medication within the thirty days prior to randomization
* Unable or unwilling to use adequate contraception
* Pregnant, breastfeeding, or plans to become pregnant within the next 2 years

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No